0
Articles   |    
Methylphenidate in Tardive Dyskinesia
WILLIAM E. FANN; JOHN M. DAVIS; IAN C. WILSON
Am J Psychiatry 1973;130:922-924.
View Article Information
Assistant Professor, Department of Psychiatry and Pharmacology, Duke University Medical Center, P.O. Box 3812, Durham, N.C. 27710, and Staff Psychiatrist, Veterans Administration Hospital, Durham
Professor of Psychiatry and Associate Professor of Pharmacology, Department of Psychiatry and Pharmacology, Vanderbilt University Medical School, Nashville, Tenn.
Research Psychiatrist, Dorothea Dix Hospital, North Carolina State Department of Mental Health, Raleigh, N.C.
1973, The American Psychiatric Association
text A A A
PDF of the full text article.
Abstract
Methylphenidate, an amphetamine-like central nervous system (CNS) stimulant used successfully in reversing acute neuroleptic-induced neurological symptoms, was given in a placebo-controlled study to 17 patients with tardive dyskinesia. On global ratings three subjects were improved, six showed an increase in symptoms, and eight showed no changes. The authors conclude that methylphenidate is not effective in tardive dyskinesia and that the results of this study are in keeping with present knowledge about CNS pharmacology.Abstract Teaser
Figures in this Article

    Your Session has timed out. Please sign back in to continue.
    Sign In Your Session has timed out. Please sign back in to continue.
    Sign In to Access Full Content
     
    Username
    Password
    Sign in via Athens (What is this?)
    Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
    Not a subscriber?

    Subscribe Now/Learn More

    PsychiatryOnline subscription options offer access to the DSM-IV-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

    Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

    +
    +
    +

    CME Activity

    There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
    Submit a Comments
    Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
    Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

    * = Required Field
    (if multiple authors, separate names by comma)
    Example: John Doe



    Related Content
    Articles
    Books
    What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 66.  >
    What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 68.  >
    What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 69.  >
    What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 70.  >
    What Your Patients Need to Know About Psychiatric Medications, 2nd Edition > Chapter 90.  >
    Topic Collections
    Psychiatric News
    PubMed Articles